175 Discussion and future perspectives 70. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020. DOI: 10.1056/NEJMoa1911440. 71. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer 2015;51(5):587-594. (In English). DOI: 10.1016/j.ejca.2015.01.054. 72. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Brit J Cancer 2015;112(12):1888-1894. (In English). DOI: 10.1038/bjc.2015.173. 73. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015;26(1):13-21. (In English). DOI: 10.1093/ annonc/mdu378. 6
RkJQdWJsaXNoZXIy MTk4NDMw